Amikacin is under clinical development by Matinas BioPharma Holdings and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Amikacin’s likelihood of approval (LoA) and phase transition for Mycobacterium avium Infections took place on 14 Oct 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Amikacin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Amikacin overview

Amikacin is under development for the treatment of Mycobacterium avium infections (NTM infections) and other pulmonary diseases. The drug candidate is administered orally. It acts by specifically locking16S rRNA of 30S ribosomal subunit. It is an aminoglycoside antibiotic. The drug candidate is developed based on cochleate technology. It was also under development for multi-drug resistant gram-negative bacterial infections.

Matinas BioPharma Holdings overview

Matinas BioPharma Holdings (Matinas BioPharma) is a biopharmaceutical company that discovers and develops anti-infectives for orphan indications. The company develops lipid nanocrystal (LNC) technology, a drug delivery platform to deliver various molecules such as small molecules, proteins, peptides, oligonucleotides, vaccines, and gene editing technologies. Its pipeline products include MAT2203, an LNC formulation of amphotericin B used for the prevention of IFI in acute lymphoblastic leukemia; and MAT2501, an LNC formulation of amikacin used for non-tuberculosis mycobacterium infections. The company partners with pharmaceutical and biotech companies to develop its LNC platform. Matinas BioPharma is headquartered in Bedminster, New Jersey, the US.

Quick View Amikacin LOA Data

Report Segments
  • Innovator
Drug Name
  • Amikacin
Administration Pathway
  • Oral
Therapeutic Areas
  • Infectious Disease
  • Respiratory
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.